Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 14, 2022

BUY
$135.27 - $180.11 $135 - $180
1 Added 2.86%
36 $5,000
Q2 2022

Aug 08, 2022

SELL
$108.81 - $179.33 $761 - $1,255
-7 Reduced 16.67%
35 $6,000
Q1 2022

May 10, 2022

BUY
$119.61 - $157.85 $1,076 - $1,420
9 Added 27.27%
42 $6,000
Q4 2021

Feb 11, 2022

SELL
$142.57 - $190.86 $667,370 - $893,415
-4,681 Reduced 99.3%
33 $5,000
Q3 2021

Nov 08, 2021

SELL
$142.45 - $169.82 $4,985 - $5,943
-35 Reduced 0.74%
4,714 $801,000
Q2 2021

Aug 09, 2021

SELL
$135.08 - $161.1 $120,491 - $143,701
-892 Reduced 15.81%
4,749 $750,000
Q1 2021

Apr 28, 2021

BUY
$137.51 - $190.8 $765,243 - $1.06 Million
5,565 Added 7322.37%
5,641 $783,000
Q4 2020

Feb 09, 2021

BUY
$164.63 - $211.93 $12,511 - $16,106
76 New
76 $13,000

Others Institutions Holding SGEN

About Seagen Inc.


  • Ticker SGEN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,664,992
  • Description
  • Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment ...
More about SGEN
Track This Portfolio

Track Meeder Asset Management Inc Portfolio

Follow Meeder Asset Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Meeder Asset Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Meeder Asset Management Inc with notifications on news.